Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells

Figure 6

Effects of insulin-deficient Diabetes and oral treatment with alendronate on BMPC osteogenic, chondrogenic, and adipogenic potential. Diabetic and nondiabetic (control) animals were either left untreated (groups D and C) or treated for two weeks with 1 mg/kg/day of alendronate in their drinking water (groups DA and CA). BMPC were obtained from animals of all experimental groups and initially cultured in a basal medium. After confluence, BMPC were replated and submitted to lineage-specific culture conditions: (a) an osteogenic medium for 15 days to evaluate alkaline phosphatase enzymatic activity; (b) an osteogenic medium for 21 days to determine extracellular mineral nodule deposits; (c) a chondrogenic medium for 21 days to quantitate GAGs-associated Alcian blue staining; and an adipogenic medium for 10 days to measure intracellular triglyceride accumulation; (d) and lipase enzymatic activity (e). Results are expressed as the mean ± SEM. versus C; versus C; versus D; versus D.

(a)

(b)

(c)

(d)

(e)